London, United Kingdom

Jane I Lowrie

This inventor holds 1 USPTO granted patent. Top assignee: Ciba-Geigy Corporation. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jane I Lowrie

Introduction

Jane I Lowrie is a notable inventor based in London, GB. She has made significant contributions to the field of pharmaceuticals, particularly through her innovative work on rifamycin derivatives. Her research has led to advancements that exhibit valuable pharmaceutical properties.

Latest Patents

Jane I Lowrie holds a patent for "Open chain rifamycin derivatives." This patent includes compounds of the general formula where R is a lower alkyl group, and R1 is a tri-lower alkylmethylcarbonyl group. The structural elements A1-A2, A3-A4, or A5-A6 each represent ethylene or vinylene. Additionally, the elements A1-A2 and A3-A4 can represent ethylene while A5-A6 represents vinylene. The optical isomers and their salts derived from these compounds demonstrate significant pharmaceutical potential. She has been awarded 1 patent for her work.

Career Highlights

Jane I Lowrie has had a distinguished career, primarily working with Ciba-Geigy Corporation. Her role at the company has allowed her to focus on innovative research and development in the pharmaceutical sector.

Collaborations

Throughout her career, Jane has collaborated with esteemed colleagues such as Peter William Taylor and Ian Timothy Matthews. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Jane I Lowrie's contributions to the field of pharmaceuticals through her innovative patents and collaborations highlight her importance as an inventor. Her work continues to influence the industry and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…